JNJ

Johnson JohnsonC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$258.00

+15.8% vs current

Most likely

Base case

50%

Probability

Target price

$242.00

+8.6% vs current

B-

Bear case

25%

Probability

Target price

$218.00

-2.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Net read stays cautiously positive but still monitoring-oriented. The April 14, 2026 primary-source update materially improved the near-term floor, yet deterministic expected returns remain modest and the main debate has not changed: JNJ still needs sustained evidence that newer medicines and MedTech launches can outrun STELARA erosion and other execution risks before a stronger bullish stance is justified.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystQ1 beat, raised 2026 outlook, and dividend hike reinforce the near-term floorMedium impact

Johnson & Johnson reported Q1 2026 sales of $24.1B, EPS of $2.14, adjusted EPS of $2.70, raised 2026 guidance to roughly $100.8B of reported sales and $11.55 adjusted EPS at the midpoint, and separately raised the quarterly dividend 3.1% to $1.34. That combination supports the defensive-holder case, but the move looks substantially recognized already given the modest gap versus the prior analyst target median. [#8-K-2026-04-14]

2026-12-08eventDecember 8, 2026 Enterprise Business Review is the clearest dated reset pointMedium impact

Management explicitly announced a planned Enterprise Business Review for December 8, 2026. For a high-coverage large-cap, this is the most concrete forward checkpoint for management to validate the path to double-digit growth, frame portfolio priorities, and add clarity around separation execution and capital-allocation posture. [#8-K-2026-04-14]

2026-12-31catalystNew product and MedTech launch mix must outrun STELARA erosion through 2026Medium impact

The core medium-term test is whether growth from DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, SPRAVATO, electrophysiology, Abiomed, Shockwave, plus newly highlighted launches such as ICOTYDE, VARIPULSE Pro, TECNIS PureSee, and the TECVAYLI plus DARZALEX FASPRO regimen can more than offset ongoing STELARA pressure. Management said STELARA reduced Innovative Medicine growth by about 920 basis points in Q1, and the 10-K says continued global biosimilar launches will keep hurting STELARA sales, so the burden of proof remains on replacement growth. [#8-K-2026-04-14] [#10-K-2026-02-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology